Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246993 | 1.00 | CCR5 (0.85) | CCR5KCNH2 | |
| SCHEMBL4238349 | 0.92 | CCR5 (1.00) | CCR5KCNH2 | |
| SCHEMBL4238345 | 0.92 | CCR5 (1.00) | CCR5KCNH2 | |
| SCHEMBL4246087 | 0.91 | CCR5 (0.88) | CCR5KCNH2 | |
| SCHEMBL4249954 | 0.91 | CCR5 (0.88) | CCR5KCNH2 | |
| SCHEMBL4246085 | 0.91 | CCR5 (0.88) | CCR5KCNH2 | |
| SCHEMBL4249957 | 0.91 | CCR5 (0.88) | CCR5KCNH2 | |
| SCHEMBL4246782 | 0.88 | CCR5 (0.86) | CCR5KCNH2 | |
| SCHEMBL4246779 | 0.88 | CCR5 (0.86) | CCR5KCNH2 | |
| SCHEMBL13911534 | 0.86 | CCR5 (1.00) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498346-B2 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | GENZYME CORPORATION (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1896023-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138259-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| US-20050277668-A1 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277668-A1 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | CCR5, CCR2, CXCR3 | CCR5 1/4885KCNH2 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.